As the world is slowly, gradually, hopefully emerges from the shadow of COVID-19 there’s a unique opportunity to re-discover what matters most to patients.
Stakeholder expectations are high and, with all eyes on healthcare at the moment, it is essential for companies to go beyond generic commitments, says Rosanna Campbell-Gray.
The company’s senior vice president for major markets (Europe, Canada and Japan) talks about the continued evolution of pharma’s approach to communications and commercialisation.
Patient centricity has become a key aspiration for the pharma industry over the last several years, but getting entire organisations to think and behave in a patient-centric way can be chal
Companies looking to replicate a drug’s EU market success in the US will face significant hurdles unless they are fully aware of the ever-changing national and state requirements and regula
